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  16 
Abstract  17 
The lymphatics are a target for a range of therapeutic purposes, including cancer therapy and 18 
vaccination and both vesicle size and charge have been considered as factors controlling lymphatic 19 
targeting. Within this work, a range of liposomal formulations were investigated to develop a 20 
liposomal lymphatic targeting system. Initial screening of formulations considered the effect of 21 
charge, with neutral, cationic and anionic liposomes being considered. Biodistribution studies 22 
demonstrated that after intramuscular injection, anionic liposomes offered the most rapid clearance 23 
to the draining lymphatics with cationic liposomes forming a depot at the injection site. Anionic 24 
liposomes containing phosphatidylserine showed higher clearance to the lymphatics and this may be 25 
a results of preferential uptake by macrophages. In terms of vesicle size, smaller unilamellar vesicles 26 
gave high lymphatic targeting and 10-fold increases in concentration were achieved in dose escalation 27 
studies (up to 40 mg of lipids). Given that effective trafficking to the lymphatics was achieved, the next 28 
step was to enhance retention of the liposomes within the lymphatics, therefore this liposome 29 
formulation was combined with an avidin/biotin complex mechanism. The affinity of avidin for biotin 30 
allows biotinylated liposomes to complex in the presence of avidin. By pre-dosing with avidin, this 31 
biotin-avidin complex can be exploited to promote longer retention of the liposomes at the draining 32 
lymphatics. To load these small, biotinylated liposomes with protein, microfluidics manufacturing was 33 
used. Using microfluidics, protein could easily be incorporated in these small (~90 nm) biotinylated 34 
liposomes. Both liposome and protein retention at the local draining lymph nodes was demonstrated 35 
with the liposome-biotin-avidin system. These results demonstrate that microfluidics can be used to 36 
prepare protein-loaded liposomes that offer enhanced lymphatic targeting and retention of both the 37 
liposomes and entrapped antigen.  38 
  39 
Introduction 40 
The lymphatic system is an important component of the immune system and acts as a secondary 41 
circulation system to drain excess fluids, proteins and waste products from the extracellular space into 42 
the vascular system. The lymphatics have been exploited as a potential means of drug delivery as 43 
these channels can transport certain lipophilic compounds such as long-chain fatty acids, triglycerides, 44 
cholesterol esters, lipid soluble vitamins and some xenobiotics, including 45 
Dichlorodiphenyltrichloroethane (DDT) [1]. In particular, lymphatic capillaries play a vital role in the 46 
absorption and uptake of drugs into the lymphatic system and lymph nodes. The walls of lymphatics 47 
capillaries are made up of a single layer of endothelial cells that has numerous gaps and pores that 48 
permit passage of macromolecules into the capillary lumen when interstitial pressure exceeds the 49 
intraluminal lymphatic pressure [2]. The lymphatics are the primary conduit for the dissemination of 50 
metastases from many solid tumours; they play a pivotal role in the generation of immune responses 51 
and have been implicated in the pathogenesis of diseases including HIV and metastitial tuberculosis. 52 
For lymph resident diseases, lymphatic targeting of therapeutic drugs (e.g., antivirals, cytotoxics or 53 
immunomodulators) is therefore expected to provide an advantage.  54 
Parenterally administrated vaccines mainly rely on the migration of APCs to the draining lymph nodes 55 
to present the processed cargo (e.g. antigens) to the T or B cells, which are found in large numbers 56 
within the  lymph nodes [3, 4]. Therefore, promoting the delivery of vaccines into the lymphatics could 57 
improve cellular and humoural immune responses. Indeed, recent research has focused on the 58 
delivery of antigens or immunocomponents into the lymphatics as a means to enhance vaccine 59 
efficacy [5, 6]. 60 
To enhance lymphatic targeting, a range of design modifications have been applied to particulate 61 
delivery systems to enhance their drainage to the lymphatics including e.g. surface engineering [7], 62 
and optimisation of particle size and charge [8],[9]. In addition, strategies to enhance the retention 63 
(and avoid rapid clearance) of the liposomes after they reach the lymphatics have been considered. 64 
This involves administration of a dose of avidin subsequently followed by administration of biotin-65 
bearing liposomes [10]. This results in the drainage of the avidin, followed by the biotin liposomes, to 66 
the lymph nodes. Due to the high binding affinity between biotin and avidin, upon draining to the 67 
lymphatics the avidin and biotin-liposomes will cross-link and become trapped within the lymph node 68 
[11]. Biotin, also known as vitamin H, is a small molecule (MW 244) that is present in very small 69 
amounts in all living cells and is critical for a number of biological processes. The valeric acid side chain 70 
of the biotin molecule can be derivatised in order to incorporate various reactive groups that are used 71 
to attach biotin to other molecules. The strong affinity of avidin for biotin allows biotin-containing 72 
molecules in a complex mixture to be specifically bound to avidin. Avidin is a glycoprotein found in the 73 
egg white and tissues of birds, reptiles and amphibians. It contains four identical subunits having a 74 
combined mass of 67 to 68 kDa. Each subunit consists of 128 amino acids and binds one molecule of 75 
biotin, thus, a total of four biotin molecules can bind to a single avidin molecule. The extent of 76 
glycosylation on avidin is very high; carbohydrates account for about 10% of the total mass of the 77 
tetramer. Avidin has a basic isoelectric point (pI) of 10 to 10.5 and is stable over a wide range of pH 78 
and temperatures. Extensive chemical modification has little effect on the activity of avidin, making it 79 
especially useful for protein purification. However, because of its carbohydrate content and basic pI, 80 
avidin exhibits relatively high nonspecific binding properties. Avidin-biotin binding is the strongest 81 
known non-covalent interaction between a protein and ligand. The bond formation between biotin 82 
and avidin is very rapid, and once formed, is unaffected by extremes in pH, temperature, organic 83 
solvents and other denaturing agents. Due to the high binding affinity between biotin and avidin, pre-84 
dosing and clearance of avidin to the lymphatics followed by injection of biotinylated liposomes 85 
(designed to drain to the lymphatics), could result in cross-linking of the liposomes and them 86 
subsequently becoming trapped and retained within the lymph node.   87 
Therefore, this potential method of targeting of liposomes to lymphatics offers a range of advantages 88 
including the potential to both reduce non-specific organ toxicities and increase the chemotherapeutic 89 
dose to the most likely sites of loco-regional cancer metastasis. In addition, advanced lymphatic 90 
imaging tools will also improve cancer staging and reduce the need for destructive nodal dissections. 91 
Finally, targeting of liposomal sub-unit antigen systems may enhance their adjuvant activity. Thus, the 92 
aim of this study was to systematically investigate the influence of liposomal characteristics, including 93 
lipid composition, charge, particle size, and lipid dose for the lymphatic targeting, and then formulate 94 
liposomes, via microfluidics, that combine this targeting with a biotin-avidin complex strategy to 95 
enhance liposome retention in the local lymph nodes. 96 
Methods 97 
Materials 98 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 2-distearoyl-sn-glycero-3- 99 
phosphoethanolamine-N-methoxy-poly(ethylene glycol) 2000 (DSPE-PEG2000), 1,2-dioleoyl-3-100 
trimethylammonium-propane (DOTAP), L-α-phosphatidylserine (PS), 1,2-dimyristoyl-sn-glycero-3-101 
phospho-(1'-rac-glycerol) (DMPG) from Avanti lipids, Alabaster, AL, USA; Methanol and Chloroform 102 
(HPLC grade) from Thermo Fisher Scientific, Loughborough; Hydrogen peroxide, Cholesterol and 103 
Phosphate buffered saline tablets (PBS) from Sigma-Aldrich, Poole, Dorset, UK; Ultima Gold 104 
scintillation fluid and 3H-Cholesterol from Perkin Elmer, Waltham, MA; Foetal bovine serum (Heat-105 
Inactivated) from Biosera, Leicestershire, UK; THP-1 cells were obtained from Roswell Park Memorial 106 
Institute; RPMI medium was purchased from PAA , Yeovil, UK; DilC 18 1,1'-dioctadecyl-3,3,3'3'-107 
tetramethylindocarbocyanine perchlorate, from Molecular probes, Oregon, USA. H56 TB antigen was 108 
gifted by Statens Serum Institut (Copenhagen, Denmark). 109 
Preparation of liposomes 110 
Multilamellar vesicles (MLVs) were prepared by the established film technique first observed by 111 
Bangham, in the 1960s [12]. The lipids used throughout these studies were dissolved in chloroform: 112 
methanol (9:1 v/v) solution at the desired concentrations. The lipid solutions were placed in a 50 mL 113 
round-bottom spherical Quick-fit flask and the solvent was removed by rotary evaporation at about 114 
37oC. This yields a thin lipid film on the walls of the flask. The dry lipid film was hydrated by addition 115 
of 2 mL of phosphate buffer saline (PBS) and agitated vigorously until the thin lipid film was completely 116 
dissolved and transformed into a milky suspension. The hydration of the lipid film was maintained 117 
above the gel-liquid crystal transition temperature (Tc) of the phospholipids used. 118 
To generate small unilamellar vesicles (SUV), MLV were disrupted via sonication using a probe 119 
sonicator (Soniprep 150). The tip of the sonication probe (diameter ~ 9.5 mm) was placed onto the 120 
surface of the 2 mL MLV mixture. The time required for sonication varied depending on the lipid 121 
composition (approximately 2-6 minutes). The SUV suspension was then centrifuged at 3,500 g for 10 122 
minutes to remove any titanium debris released from the probe during sonication. 123 
Preparation of protein loaded liposomes using microfluidics 124 
To prepare liposomes, a Nanoassemblr™ Benchtop (Precision Nanosystems, Inc., Vancouver, Canada) 125 
was used with a 300 µm Staggered Herringbone Micromixer. The lipids at the appropriate ratio were 126 
dissolved in methanol along with DSPE-PEG 2000-Biotin (20 mol%) and H56 antigen was dissolved in 127 
PBS, 10 mM, pH 7.4 aqueous buffer. The flow rate ratio between the aqueous and solvent stream was 128 
3:1 (aq:solvent ratio) and the total flow rate was 10 mL/min. Liposomes were purified using 750 kD 129 
tangential flow (TFF) column Spectra/Por® Dialysis membrane, Biotech CE Tubing, Spectrum 130 
Laboratories, USA). Liposomes washed for 10 diafiltration cycles using PBS buffer to remove solvent 131 
and unentrapped protein. 132 
Determination of vesicle size, polydispersity and zeta potential of liposomal formulations 133 
The z-average diameter and polydispersity (pdi) of liposomes was determined by dynamic light 134 
scattering using the photon correlation spectroscopy on a Malvern Zetasizer Nano-ZS (Malvern 135 
Instruments Ltd., UK); 100 μL of the sample was diluted with the hydration phase (e.g. PBS buffer 136 
solution) up to 1 mL and the vesicle size and pdi was measured at 25 °C. The zeta potential was also 137 
measured on Malvern Zetasizer Nano-ZS (Malvern Instruments Ltd., UK) at 25 °C. To measure the zeta 138 
potential, 100 μL of liposome suspension was diluted in 1 mL of its aqueous phase (1:300 v/v PBS). 139 
Quantification of the protein or antigen loading within the formulations 140 
Quantification of the protein loading within the liposomes was performed by reverse phase HPLC (RP-141 
HPLC) using a UV detector (Agilent Technologies, Edinburgh, UK). A Jupiter 5 µ C18(2) column 142 
(Phenomenex, Cheshire, UK) pore size 300A was used as stationary phase. For the preparation of the 143 
standards and samples, protein alone or liposomes loaded with protein, were diluted in 50% PBS/IPA 144 
(1:1 v/v). A gradient elution method was followed where both mobile phases contain the same 145 
solvents in different proportions (Mobile phase A: 90% H20, 10% acetonitrile and 0.1% TFA; Mobile 146 
phase B: 70% acetonitrile, 30% H20 and 0.1% TFA). The column temperature was set at 60°C, the 147 
injection volume was 50 µL and the flow rate 1 mL/min. 148 
Cryo transmission electron microscopy of liposomes 149 
Liposome suspensions were diluted 1:10 with dilution buffer at room temperature immediately prior 150 
to vitrification. Samples were preserved by vitrification and supported on holey carbon films on 400-151 
mesh copper grids. Vitrified samples were prepared by applying an 8 μL drop of sample suspension to 152 
a cleaned grid, blotting away with filter paper, and immediately plunging into liquid 30% 153 
propane/ethane refrigerated in liquid nitrogen. Grids were stored under liquid nitrogen until 154 
transferred to the electron microscope for imaging. Electron microscopy was performed using a JEOL 155 
2010 FEG Transmission Electron Microscope (TEM) operating at 200 kV at Warwick University, UK. 156 
Vitreous ice grids were transferred into the electron microscope using a cryostage that maintains the 157 
grids at a temperature below −170°C. Images of each grid were acquired at multiple scales to assess 158 
the overall distribution of the specimen. After identifying potentially suitable target areas for imaging 159 
at lower magnifications, pairs of high magnification images were acquired using Image J software. 160 
General particle selection was based on the following criteria: particles were not selected if they were 161 
over the carbon film surrounding the hole or touching the edge of the carbon film. 162 
Liposome stability in simulated biological media 163 
Liposome systems were immersed in PBS buffer and/or in FBS, in a 50% v/v mixture with PBS buffer, 164 
in order to mimic in vivo conditions. Measurements of particle size and zeta potential of the systems 165 
was carried out via dynamic light scattering using a ZetaPlus analyser (Brookhaven Instrument 166 
Corporation). Upon the addition of each liposome batch in PBS buffer to an equal volume of FBS/PBS 167 
(50% v/v), samples were incubated in a water bath at 37 °C over 24 hours. At various intervals across 168 
this time period, the samples were centrifuged (Beckman Coulter - 125,000×g, 4 °C, 45 mins), prior to 169 
measurements of particle size and zeta potential as previously conducted. 170 
In vitro studies 171 
Cell uptake studies were performed using the human monocyte cell line THP-1 as previously described 172 
[13, 14]. THP-1 cells were resuspended in fresh medium (RPMI 1640 + 10% v/v FCS) at a density of 5 × 173 
105 cells/mL and stimulated for 48 h with 100 nM dihydroxyvitamin D3 to differentiate cells. Prior to 174 
use, cells were resuspended at 2 × 106 cells/mL in fresh RPMI with 10% (v/v) FCS. Liposomes (1 mg/mL) 175 
were labelled with 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate) (DilC) (0.1 mol 176 
%) by inclusion of the lipid (dissolved in solvent) in the solvent evaporation stage of liposome 177 
production (as described above). To ensure that all formulations incorporated the DilC fluorophore 178 
equally, the fluorescence was measured using a fluorimeter. Fluorescently labelled liposomes were 179 
diluted to a concentration of 10 μg/mL in RPMI, mixed with cells (1:1) in tissue culture plates, and co-180 
cultured at 37 °C in 5% CO2. At various time-points, 200 μL of co-culture was removed and mixed with 181 
200 μL ice-cold RPMI prior to immediate analysis. Association of fluorescent liposomes with THP-1 182 
macrophages was analysed using non-fixed cells via flow cytometry using a Beckman-Coulter FC500 183 
cytometer (High Wycombe, UK). For each sample a minimum of 10 000 events was examined. 184 
Biostribution studies 185 
All in vivo studies were conducted under the regulations of the Directive 2010/63/EU. All protocols 186 
have been subject to ethical review and were carried out in a designated establishment. Inbred 187 
BR/NMRI strain of mice used for research in biodistribution studies and were obtained from Aston 188 
Biomedical facility, Aston University, UK. BR/NMRI mice were used for in vivo biodistribution studies 189 
in order to study the movement of liposomes from the site of injection (SOI). Mice were housed under 190 
conventional conditions (22 °C, 55 % humidity, 12 h day/night cycle) in their experimental groups (8 191 
mice/cage) and were given a standard diet ad libitum. All mice were female and purchased at 6-9 192 
weeks of age. Groups of 3 mice were used to study biodistribution of liposomal formulations for each 193 
time point and five time points were selected for termination of the mice which were 1 h, 1, 2, 4 and 194 
8 days after the injection. Mice were injected 50 µL intramuscularly to the left quadriceps muscles. 195 
Muscle from the site of injection (left quadriceps) in case of intramuscular injection, spleen, popliteal 196 
lymph nodes (PLN) and other relevant lymph nodes were collected after termination of each mouse 197 
by cervical dislocation at relevant time points during the study. Each tissue sample was weighed in a 198 
plastic scintillation vial. To solubilise the tissues, 2 mL of 10 M NaOH were added and the samples 199 
incubated at 60 °C for 5 h. After all tissues were solubilised, 200 µL hydrogen peroxide was added and 200 
kept for 2 h at 60 °C to bleach the organs and solution completely.  201 
3H and 125I has energy overlap at 0-18.6 keV (3H) and 0-80 keV (125I) and this leads to an over-spill 202 
due to iodine in tritium region. To eliminate this over-spill, a calibration curve was prepared at a plot 203 
of the cpm values derived from the scintillation counter due to 125I (x-axis) against the cpm values 204 
derived from the scintillation counter due to 3H (y-axis) was made and the line of best fit and equation 205 
derived for samples below 50,000 cpm (~2% of the dose or less) and those above 50,000 cpm (~2% of 206 
the dose or more). These two equations were used to eliminate the effective interference that the 207 
125I would have on the 3H values determined by scintillation counting. 10 mL Ultima Gold™ 208 
scintillation fluid added to each sample and presence of 3H and 125I was quantified using a method 209 
for 3H-125I detection protocol using a TriCarb 2810 Liquid Scintillation Counter (Packard). 210 
Simultaneously, triplicate samples of the original dose in another plastic scintillation vials were made 211 
and measured for presence of 3H and 125I to calculate % original dose of liposomes (3H) and antigen 212 
(125I). 213 
Immunisation Studies  214 
Female 6-8 week-old C57BL/6 mice were used to study immunisation of above formulations. 5 mice 215 
per group were injected i.m (50 μL) into the left quadriceps with formulations prepared on the day of 216 
injection. Each mouse received a total of 3 injections on day 1, 14 and 28. The mice were vaccinated 217 
as follows: Group 1 was the control group, this group was vaccinated with 0.1 mg/mL H56 antigen; 218 
group 2 was vaccinated with H56 loaded DSPC:Cholesterol:PS; group 3 was vaccinated with H56 219 
loaded DSPC:Cholesterol:PS:PEG2000 biotin (20 mole%) liposomes, and finally group 4 was vaccinated 220 
with the same formulation as group 3 plus avidin, which was injected on the same quadriceps 2 hours 221 
prior the main immunisation at a concentration of 200 µg per dose (50 µL). 222 
Antibodies were detected in the serum of tail-bled mice. Blood was and placed into Eppendorfs coated 223 
with 1% w/v heparin. All tubes were centrifuged (12,000 rpm, 10 minutes) and the supernatant from 224 
each tube was placed in a new Eppendorf and frozen (- 20 °C) until use. Serum was consequently 20-225 
fold diluted in PBS if the volume ratio of red blood cells:sera is assumed to be 1:1. To detect antibodies 226 
in serum, standard enzyme-linked immunosorbent assays (ELISA) were used. ELISA pates (MaxiSorp) 227 
were coated overnight at 4 °C with 100 μL H56 in carbonate buffer (0.5 μg/well). Plates were washed 228 
three times to remove unbound antigen; the wash buffer used throughout was PBST (0.2% Tween 20, 229 
in PBS (10 mM)). Plates were blocked for 1.5 h at room temperature with 2% BSA (200 μL/ plate). After 230 
blocking, the plates were washed three times with PBST. 11 µL of the serum was added into the first 231 
well containing 100 µL of 1% BSA in PBS and mixed up and down with the pipette. Serial dilutions 232 
(1/10) were done by transferring 11 µL from the first well to the next one and so on 7 – 12 times. 233 
Lastly 11 μL of diluted serum was removed from the last wells so that the total volume of serially 234 
diluted serum in all wells was 100 μL. Each sample was investigated in duplicate. Plates were incubated 235 
at room temperature for 2 h followed by three washes with PBST and addition of 100 μL of isotype 236 
specific immunoglobulin diluted 1:5000 (IgG1) or 1: 20000 (IgG2c) in 1% BSA. After 1 h at room 237 
temperature all plates were washed again five times and 100 μL of TMB substrate added per well. 238 
After 20 mins of incubation in dark with TMB substrate, reaction was stopped by adding 100 μL/well 239 
of 0.2 M sulfuric acid. Absorbance were measured at 450 nm. The results were expressed as the log10 240 
value of the reciprocal of the end point dilution which gave an optical density (O.D) of 0.2 or above. 241 
Spleens and popliteal lymph nodes from each mouse were isolated and processed on day 49. 242 
Individual spleens were placed in 15 mL falcon tubes containing 2 mL of PBS and kept ice-cold whereas 243 
the lymph nodes from each group were pooled together. Spleens and lymph nodes were forced 244 
through a metal mesh using the bottom part of a 3 mL plastic syringe and transferred back to a falcon 245 
tube filled with 12 mL of PBS. Samples were washed twice via centrifugation at 1800 rpm for 5 min at 246 
4°C. Cells were resuspended in 1.8 mL or 0.5 mL of complete RPMI (RPMI supplemented with HEPES, 247 
penicillin-streptomycin, L-glutamine, sodium pyruvate, non-essential amino acids, mercaptoethanol 248 
and 10% heat inactivated FCS) for spleens and lymph nodes respectively. Cells were counted and 249 
diluted in complete RPMI to a final concentration of 2 x 106 cells/mL. Cells were counted using the 250 
tryphan blue exclusion assay. Briefly, cells were dyed with tryphan blue in a 1:10 ratio (10 µL cells: 90 251 
µL tryphan blue). Subsequently, 100 µL were placed on a haemocytometer and cells were counted. 252 
Once the cells were diluted to the same concentration, 100 µL of this diluted cells were plated on a 253 
Nunclon 96-well round bottom (Fisher scientific, Loughborough, UK). Cells were stimulated with either 254 
100 µL of ConA (5 µg/mL) which serves as a positive control since it stimulates the production of 255 
cytokines, RPMI media as a negative control, or H56 antigen (5 µg/mL) as the investigated antigen. 256 
Splenocytes and lymph nodes from immunised mice were incubated at 37°C, 5 % CO2 and 95 % 257 
humidity for 72 hours. After 3 days of incubation, supernatants were harvested (approximately 160 258 
µL) and stored at -20°C for further processing. Supernatants from restimulated splenocytes and lymph 259 
nodes were analysed using a sandwich ELISA protocol for the production of cytokines IL-17 and IFN-ɣ. 260 
Plates were coated with the specific capture antibody diluted in carbonate buffer, either purified anti 261 
mouse IL-17 (1:500 dilution) or IFN-ɣ (1:1000 dilution) overnight at 4°C. Next day plates were emptied 262 
and blocked for 1.5 – 2 hours at room temperature with 200 µL/well PBS containing 2% milk powder. 263 
Plates were washed and samples and standards were diluted in 2% BSA in PBS and incubated at room 264 
temperature for 2 hours (total volume in all wells was 100 µL). Plates were washed 3 times and biotin 265 
conjugate was diluted in 1% BSA in PBS (IL-17 1:2000, IFN-ɣ 1:5000) and 100 µl were added on each 266 
well. Plates were incubated for an hour at room temperature followed by washing and 30 min 267 
incubation with 100 µL/well of HRP-streptavidin in 1% BSA (1:5000). Plates were washed and TMB 268 
substrate (room temperature) was applied to the plates 100 µL/well. After approximately 15 minutes 269 
the reaction was stopped by adding 100 µL/well 0.2 M sulfuric acid. 270 
Statistical analysis  271 
Statistical analysis was carried out by one-way ANOVA (analysis of variance) at a significance level of 272 
0.05. All statistical analyses were performed using Graph Pad Prism software (Version 6.0 for 273 
Windows). Statistically significant differences are noted (P < 0.05). Each experiment was carried out 274 
in triplicate with the average mean result recorded ± the standard deviation of this set of results 275 
(represented as error bars). 276 
Results 277 
The choice of anionic lipid within the liposomes impacts on the distribution to the lymphatics and 278 
may be influenced by phagocytic uptake 279 
Given that previous research has suggested the neutral liposomes clear more effectively to the 280 
draining lymphatics [9, 15, 16], we initially tested four liposomes of different charges: neutral - 281 
DSPC:Cholesterol, anionic -  DSPC:Chol:PS and DSPC:Chol:DMPG and cationic - DSPC:Chol:DOTAP.  All 282 
liposomes were approximately 100 nm in size and PDI values of 0.2 with their zeta potential being 283 
near neutral (DSPC:Cholesterol), anionic (with the addition of PS or DMPG) or cationic (with the 284 
inclusion of DOTAP) respectively (Figure 1 A). These four formulations were injected intramuscularly 285 
and clearance from the injection site monitored. From Figure 1B, we see the cationic DOTAP 286 
formulation shows high retention at the injection site with approximately 40% retained after 192 h (4 287 
days). The neutral (DSPC:Chol) and anionic (PS and DMPG based formulations) showed faster 288 
clearance with the DSPC:Chol:PS formulation showing the fastest clearance; only 23 % of the liposome 289 
dose remaining after 24 h. These clearance profiles translated to appearance at the draining local 290 
lymph node (popliteal lymph node; POP), with DSPC:Chol:PS liposomes showing the highest 291 
accumulation (approximately 30% at 24 h) within the lymph node (Figure 1C). When considering the 292 
interaction of these formulations with the biological environment, the cationic liposomes rapidly 293 
aggregate in the presence of simulated biological media (50% v/v foetal bovine serum (FBS), whilst 294 
there is no notable aggregation occurring with the neutral nor anionic formulations (Figure 1D). The 295 
FBS media consisted of 50% FBS and 50% PBS buffer (v/v) as blood plasma represents ~50% of total 296 
blood volume, thus mimicking the physiological conditions that the liposomal drug may encounter 297 
upon injection. This suggests that the cationic liposomes will aggregate upon injection and form a 298 
depot at the injection site. However, this does not explain the differences in clearance of the neutral 299 
and anionic formulations. The neutral and both anionic liposome formulation are similar in size and, 300 
due to the presence of cholesterol within their formulation, have similar low transition temperatures.  301 
 302 
Figure 1. The effect of charge on liposome biodistribution. Mice were injected intramuscularly with 4 303 
formulations, as shown in (A). The rate of clearance from the injection site (B) and the popliteal lymph 304 
node (POP) (C) are shown as a percentage of injected dose. The degree of aggregation of these 305 
formulations when exposed to simulated interstitial fluid is shown in D. Results are expressed of the 306 
mean ± SD of 3 mice per group.  307 
Given that clearance of the liposomes from the injection site may also result from phagocytic cell 308 
uptake, we compared the cellular uptake of the neutral and anionic liposome formulations using the 309 
human macrophage cell line THP-1 [14] (Figure 2). The uptake studies were performed in vitro using 310 
fluorescence-labelled liposomes co-cultured with THP-1 derived macrophages at a final lipid 311 
concentration of 10 µg/mL. The proportion of macrophages associated with fluorescent liposomes, 312 
and the relative amount of fluorescence associated, was quantified using flow cytometry. Figure 2 313 
shows that liposomes containing PS are more rapidly taken up by the macrophages that their DMPG 314 
and neutral liposome counterparts. For PS liposomes, around 80% of the cells were associated with 315 
the liposomes compared to DMPG liposomes which had approximately 40% uptake (Figure 2A); this 316 
may be due to the presence of PS serving as a recognition signal for phagocytosis by macrophages 317 
[17]. Indeed the rapid uptake of the PS liposomes could be negated by PEGylating the DSPC:Chol:PS 318 
liposomes. With this formulation, the macrophages showed only 20 % of cells association with 319 
fluorescence (Figure 2B). This proves that uptake of these liposomes to cells is not only dependent on 320 
the general charge of the liposomes but also based on the anionic lipid adopted within the formulation 321 
with PS liposomes showing selective uptake.  322 
  323 
Figure 2. The effect of formulation on liposome update by macrophages. Association of liposomes 324 
with THP-1 (macrophages) cells was investigated by flow cytometry. (A) Percentage of THP-1 cells 325 
positive for fluorescence surface bounded or internalized) with macrophages at 0 mins and 180 mins. 326 
(B) Fold increase of mean fluorescent intensity of THP-1 cells co-cultured with above liposome 327 
formulations. Results denote mean ± SD of 3 independent experiments.  328 
 329 
The size of anionic liposomes also influences liposome clearance from the injection site and 330 
movement to the lymphatics 331 
Several studies have suggested that smaller vesicles can clear to the draining lymphatics (e.g. [18-21]), 332 
therefore we also tested and confirmed this with the DSPC:Chol:PS formulation formulated as small 333 
(<100 nm; Figure 3A) and large (approx. 900 nm; Figure 3B) vesicles. The results in Figure 3C and D, 334 
show that the smaller liposomes clear more rapidly from the injection site and move to the draining 335 
lymph node with only low levels (< 5 %) of the MLV being detected at the popliteal lymph node (Figure 336 
3D). Interestingly, uptake by macrophages was also higher for the SUV compared to the MLV (Figure 337 
3E and F). So it is not clear if the difference in clearance is due to drainage of the liposomes or their 338 
phagocytic uptake and maybe an accumulation of both.  339 
 340 
Figure 3 The effect of liposome size on the clearance of liposomes from the injection site to the local 341 
draining lymph node. DSPC:Chol:PS liposomes were formulated as MLV (A) and SUV (B). Mice were 342 
intramuscular (i.m.) injected with SUV and MLV liposomes and the liposomes at the injection site (C) 343 
and popliteal lymph node (PLN) (D) are shown. (E) Percentage of THP-1 cells positive for fluorescence 344 
surface bounded or internalized) with macrophages at 0 mins and 180 mins. (F) Fold increase of mean 345 
fluorescent intensity of THP-1 cells co-cultured with above liposome formulations. Results are 346 
expressed of the mean ± SD of 3 mice per group.  347 
 348 
A dose-dependency of the accumulation of liposomes in regional lymph nodes  349 
To study the effect of anionic lipid dose on lymphatic targeting of liposomes, liposomes with increasing 350 
amount of lipid dose of PS (i.e. 48, 240 and 480 µg/dose) were injected intramuscularly. The recovery 351 
of liposomes (expressed as dose of PS) at the site of injection is shown in figure 4A; approximately 40 352 
to 50 % of PS dose was recovered at injection site at 1 h. All formulations were cleared from site of 353 
injection within 48 h (Fig 4A). The increasing trend shows no saturation of the lymphatic absorption 354 
process was observed over the dose range investigated until 24 h. However, lipids were seen to be 355 
cleared from lymph nodes after 48 h of injection; 12 µg dropped to 8 µg at 24 and 48 h respectively 356 
when 48 µg of PS was injected (Fig 4B). A similar trend was seen in case of 5-fold and 10-fold doses of 357 
PS (Figure 4C) when expressed as percentage dose, demonstrating that at the concentrations tested, 358 
saturation did not occur. This suggests that the clearance from the injection site and movement to the 359 
lymph node may be both a physical and cellular process.  360 
 361 
Figure 4. The effect of lipid dose on lymphatic uptake in mice following intramuscular injection of 362 
liposome formulations. Increasing doses of DSPC:Chol:PS liposomes were injected and the amount of 363 
liposomes at the injection site measured and shown as (A) Amount of PS (µg) at Injection site, (B) 364 
Amount of PS (µg) at Popliteal lymph node (PLN), (C) Percent dose of DSPC:Cholesterol:PS liposomes 365 
at three different escalated doses at popliteal lymph nodes. Results are expressed of the mean ± SD 366 
of 3 mice per group 367 
 368 
Exploiting a biotin-avidin complex enhances retention of liposomes at the draining lymph node 369 
Given we had identified a liposome formulation that offered rapid clearance to the local lymphatics, 370 
the next stage was to develop the formulation further to offer enhanced retention at the lymph node. 371 
To achieve this, an avidin-biotin complexing process was investigated [11]. To allow us to effectively 372 
load the liposomes being formulated we also adopted microfluidics as the manufacturing process. We 373 
have recently demonstrated that microfluidics offers the potential to prepare small unilamellar 374 
vesicles with high protein loading [22]. Therefore, two liposomes formulations were prepared using 375 
Nanoassemblr based on DSPC:Chol:PS:DSPE-PEG2000 but with one formulation having biotin 376 
conjugated to the PEG. Initially both liposome formulations were prepared without protein and both 377 
formulations were similar in size and charge (100 - 120 nm; 0.19 – 0.22 PDI; zeta potential -16 to -20 378 
mV; Figure 5). Mice were intramuscularly injected with either non-biotinylated PS-PEG 2000 liposomes 379 
(DSPC:Chol:PS-PEG2000), biotinylated liposomes without pre-dosing of avidin 380 
(DSPC:Chol:PS:PEG2000-biotin) or biotinylated liposomes with pre-dosing of avidin  2 h prior to 381 
liposome administration (DSPC:Chol:PS:PEG2000-biotin-avidin) (Figure 5). 382 
 383 
Figure 5. The effect of exploiting a biotin-avidin complex system for lymphatic targeting.. Mice were 384 
intramuscularly injected with either DSPC:Chol:PS:PEG2000 (6:4:2.5 µmoles; 2 mole% PEG) or 385 
DSPC:Chol:PS:PEG2000-biotin (6:4:2.5 µmoles; 2mole% PEG-biotin). Two groups of mice received the 386 
biotin-coated liposomes, one without pre-dosing of avidin (DSPC:Chol:PS:PEG2000-biotin) and one 387 
group receiving a pre-dose of avidin (DSPC:Chol:PS:PEG200-biotin-avidin). The percentage (%) injected 388 
dose of biotinylated liposomes in mice following intramuscular injection A: Injection site, B: Popliteal 389 
lymph node (POP), C: Inguinal lymph node (ILN) and D: Mesenteric lymph node (MLN). Results are 390 
expressed of the mean ± SD of 3 mice per group. 391 
 392 
In terms of clearance from the injection site, all three formulations rapidly cleared; approximately 50 393 
% of the initial dose remained at the injection site after 24 h and approximately 20 % at 48 h suggesting 394 
that the presence of biotin on the liposome formulation did not influence clearance from the injection 395 
site (Figure 5A). However, upon clearing the injection site, mice pre-dosed with avidin and 396 
subsequently injected with biotinylated liposomes (DSPC:Chol:PS:PEG2000-biotin-avidin) showed 397 
higher lymph node retention (Figure 5B to D) with approximately 30 % after 24 h (P < 0.05) at the 398 
popliteal lymph node compared to the two other groups (Figure 5B). Furthermore, the avidin-399 
biotinylated liposome combination showed prolong retention at the popliteal lymph node with 400 
approximately 20 % of the dose remaining after 8 days whereas non-biotinylated liposomes showed 401 
less than 1% of dose at lymph node on  day 8 (Figure 5B) suggesting the formation of a biotin-avidin 402 
complex within the lymph node and increased accumulation and retention at draining lymph nodes 403 
[10]. The use of the biotin-avidin complex system also promoted higher retention at other nearby 404 
lymph nodes, especially the inguinal lymph node which showed approximate 15 % (P< 0.05) uptake at 405 
96 h when pre-dosed with avidin, yet liposomes without biotin or avidin showed no uptake in any 406 
secondary draining lymph nodes (Figure 5C and 5D). 407 
Biotinylated liposomes offer enhanced trafficking and retention of liposomes and their entrapped 408 
moiety to local and secondary lymph nodes. 409 
Using a dual-radiolabelling technique, the biodistribution of liposomes and antigen was studied in 410 
mice (Figure 6). Two liposome formulations were prepared entrapping the H56 protein antigen (Table 411 
1) with the liposomes being 90 to 115 nm in size and protein loading being approximately 20% for the 412 
PS liposomes and 10% for the PEGylated PS liposomes.  Figure 6A shows the draining of PS liposomes 413 
along with the antigen from site of injection. Only 10 % of liposomes and antigen was present at site 414 
of injection at 48 h. These liposomes then move to the popliteal lymph node along with the entrapped 415 
antigen (Figure 6B), with no detectable levels of liposomes or protein being noted at the inguinal or 416 
mesenteric lymph node (Figure 6C and D respectively). In comparison, the combination of pre-dosing 417 
with avidin and subsequent injection of biotinylated liposomes resulted in a faster clearance of the 418 
liposomes from the injection site with only 23 % of liposomes and 13 % of antigen respectively being 419 
present at 6 h (Figure 6E). In parallel to this clearance, rapid accumulation of the liposomes and 420 
antigen is seen at the popliteal lymph node with approximately 35 % of both the liposomes and 421 
antigen locating at this lymph node after only 6 h and 13% of the antigen still being present after 4 422 
days (Figure 6F). In the case of the inguinal and mesenteric lymph nodes, notable levels (up to 25%) 423 
of the liposomes and antigen accumulated (Figure 6G and H respectively). This is compared to no 424 
liposome or antigen being detected at either site when the avidin-biotin complexation was not used. 425 
These results demonstrate that the biotin-liposome/avidin method increasing the deposition of 426 
liposomes in lymph nodes delivers their entrapped moiety to the draining lymph nodes and that this 427 
targeting and retention was also measured in secondary lymph nodes such as inguinal or mesenteric 428 
lymph node. 429 
 430 
Table 1: Physicochemical characteristics (particle size, PDI and ZP) and loading efficiency of the 431 
vaccine formulations prepared for the immunisation study. All vaccine formulations were loaded 432 
with a final H56 concentration of 0.1 mg/mL.  Non-encapsulated antigen was removed by TFF in 433 
order to have the same antigen concentration in all the vaccines. 434 
Formulations Lipid ratio 
(µmoles) 
Particle size 
(nm) 
PDI Zeta 
Potential 
(mV) 
Antigen 
loading (%) 
DSPC:Cholesterol:PS 6:4:2.5 113.3 ± 2.3 0.15 ± 0.02 -41.1  ± 4.6 18.7 ± 4.3 
DSPC:Cholesterol:PS:DSPE-PEG 
2000 biotin (20 mole %) 
6:4:2.5 + 20 
mole% 
87.5 ± 6.7 0.24 ± 0.02 -11.5 ± 1.9 9.9 ± 3.2 
 435 
 436 
Figure 6. Biodistribution of lymphatic targeted liposomes and antigen (5 µg/dose H-56) in mice. Two 437 
liposome formulations were tested (avidin was intramuscularly injected 2 hours prior to injection of 438 
the main formulation). Liposomes and antigen dose was monitored at the site of injection (A & E), 439 
popliteal lymph node (B & F), Inguinal lymph node (C & G) and mesenteric lymph node (D & H) were 440 
isolated and counted for % injected dose of DSPC:Chol:PS and DSPC:Chol:PS:DSPE-PEG 2000 Biotin (20 441 
mole%) formulations respectively. Results represent the mean ± SD of three replicate batches (n = 3). 442 
 443 
Enhanced retention at the lymph node did not impact on immune responses 444 
To test if this enhanced delivery and retention of the liposomes and their entrapped protein generated 445 
immune responses, immune responses against the entrapped antigen were also evaluated (Figures S1 446 
and S2).  The impact of lymphatic retention was tested by comparing mice which did and did not 447 
receive a pre-dose of avidin prior to receiving an intramuscular injection of biotinylated liposomes 448 
incorporating the H56 protein antigen. Comparing across the liposome formulations, there is no 449 
significant difference in antibody (Figure S1) or cytokine (Figure S2) responses in both the spleen and 450 
lymph nodes. This suggests that re-directing and retaining liposomes that do not contain 451 
immunostimulatory agents does not promote notable immune responses.  452 
 453 
 454 
Figure S1. Antigen-specific (A) IgG1 and (B) IgG2c responses in mice immunised with liposomes with 455 
and without the biotin-avidin complex formulation. C57BL/6 mice were intramuscularly immunised 456 
with the liposomes incorporating 5 µg H56 and humoural responses were analysed in blood. H56-457 
specific IgG1 (A, B, C) and IgG2c (D, E, F) serum responses detected by ELISA on sera collected (A, D) 458 
7, (B, E) 21 and (C, F) 49 days after i.m. immunization. Antibody titres were expressed as the reciprocal 459 
log of the highest dilution with an OD value ≥0.2 after background subtraction. 460 
 461 
 462 
Figure S2. Cytokine production in splenocyte and lymph node culture supernatants (IL-17 and IFN-ɣ) 463 
in mice immunised with liposomes with and without the biotin-avidin complex system. C57BL/6 mice 464 
were intramuscularly immunised with 5 µg H56 incorporated in the various liposome formulations and 465 
spleens were collected 3 weeks after the last immunization. Levels of IFN-ɣ in the spleen (A), popliteal 466 
lymph nodes (B), and IL-17 in the spleen (C) and lymph nodes (D) were measured. Values, expressed 467 
as picograms per milliliter, are reported as the mean value ± SD of H56-stimulated of five animals per 468 
group. 469 
Discussion  470 
It has been extensively studied and published that lipid composition and charge affect liposomal 471 
biodistribution particularly, lymphatic uptake and targeting [23-25]. Building on this, from our studies 472 
we are able to confirm that in addition to the formulation of small negatively charged liposomes, 473 
incorporation of phosphatidylserine within the liposomal bilayer can promote higher delivery of 474 
liposomes and their entrapped moiety to local draining lymph nodes compared to other negatively 475 
charged liposomes. This enhanced trafficking of small PS liposomes may be the result of macrophage 476 
uptake with PS serving as a recognition signal for phagocytosis by macrophages [26] and triggering 477 
recognition by macrophages [27] with PS liposomes, thus potentially mimicking the effects of 478 
apoptotic cells on these phagocytes to induce the secretion of anti-inflammatory molecules and to 479 
inhibit the maturation of dendritic cells [28].  480 
PS is recognised to exhibit anti-inflammatory properties. During apoptosis, exposure of PS on the outer 481 
leaflet of the cytoplasmic membrane acts as an apoptotic signal for phagocytes. Phosphatidylserine 482 
recognition of activated phagocytes inhibits pro-inflammatory cytokine production such as Interleukin 483 
6 (IL6) and Prostaglandin E2 (PGE2), in Interleukin 1 beta (IL-1β) stimulated in vitro and in vivo animal 484 
models [29], through induction of active anti-inflammatory or suppressive properties in macrophages 485 
[30]. Indeed, a previous study has shown the effects of PEGylated PS‐containing liposomes on the 486 
expression of two inflammation associated cytokines, tumour necrosis factor‐α (TNF‐α) and 487 
transforming growth factor‐β (TGF‐β), in the murine macrophage‐like cell line RAW 264.7 [31]. These 488 
results demonstrated that the incorporation of PEGylated PS‐containing liposomes into cells 489 
decreased compared with non‐PEGylated PS liposomes, suggesting that the interactions between PS 490 
and the PS receptors that influence TNF‐α and TGF‐β levels were differentially affected by the 491 
PEGylation of PS liposomes [31, 32]. As PEGylated PS containing liposomes are capable of efficiently 492 
inhibiting the inflammatory cytokine TNF‐α without upregulating TGF‐β mRNA [33], they demonstrate 493 
promising anti‐inflammatory effect. Within our studies, we also demonstrate reduced uptake when 494 
we PEGylate the PS containing liposomes. 495 
Our results also investigate the potential of the avidin/biotin complexation to enhance retention at 496 
the lymphatics. Several published studies previously have shown the ability of the avidin/biotin system 497 
to effectively target to the lymph nodes [34, 35]. For example, biotin coated liposomes were injected 498 
subcutaneously in both hind feet of rabbits, followed by an adjacent injection of avidin; 14 % of 499 
injected biotinylated liposomes retained at popliteal lymph nodes and 2 % in iliac lymph node after 24 500 
h. Animals without avidin injection showed only 2 % and 0.3 % injected liposomes retention in 501 
popliteal and iliac lymph node respectively [10]. Moreover, a study in ovarian cancer bearing rats 502 
showed accumulation and retention of liposomes in the mediastinal lymph nodes and diaphragm for 503 
up to 22 h post-injection i.p. of biotinylated liposomes followed by avidin. Whereas, without an 504 
adjacent avidin injection, the biotin-liposomes quickly cleared the peritoneal cavity of the tumor-505 
bearing rat by moving through the lymph nodes and returning to the blood circulation [34]. As 506 
demonstrated in our studies, a major advantage of using the biotin-liposome/avidin system within our 507 
studies is the prolonged retention and uptake by secondary lymph nodes such as mesenteric and 508 
inguinal lymph node due to the formation of avidin/biotin complex in vivo at the lymph node level 509 
[10]. Upon trafficking of the biotinylated liposomes to these lymphatics, aggregation of the biotin-510 
coated liposomes with avidin occurs. These aggregated liposomes then become trapped in this or the 511 
next encountered lymph node [10]. This mechanism resulted in enhanced delivery and retention to 512 
the lymphatics of both the liposomes and entrapped protein. This re-directing of the liposomes and 513 
retention of non-adjuvanted liposomes did not induce notable immune responses. For example, if 514 
these formulations were to be benchmarked to a known liposomal adjuvant prepared from 515 
dimethyldioctadecylammonium bromide (DDAB) and trehalose 6,6′-dibehenate (TDB) using the H56 516 
antigen IFN-g responses in the spleen can be 15 times higher whilst IL-17 is 6 times high [36]. There is 517 
the potential that the liposomes may have driven a different type of immune response (e.g. IL-4 and 518 
IL-10); however given the biotin is conjugated to the liposomes via PEG, it is possible that this, 519 
combined with the lack of immune-stimulatory lipids within the formulation, circumvents any 520 
adjuvant activity.  521 
Furthermore, within this study we demonstrate the application of microfluidics to formulate 522 
lymphatic targeting liposomes incorporating protein. A known issue during liposomes manufacturing 523 
is the low loading and protein degradation linked to the harsh conditions during sonication as 524 
traditional manufacturing methods, high shear stress conditions and high temperatures [37]. Within 525 
this work, biotinylated liposomes were successfully manufactured using microfluidics giving various 526 
advantages over traditional lipid thin film hydration method followed by extrusion. Microfluidics has 527 
been shown to be quick with reproducible vesicle sizes obtained with protein loading being markedly 528 
higher (up to 10 fold depending on the liposome formulation) in comparison with traditional passive 529 
loading technique [38]. 530 
Overall, a biotin/avidin complex mechanism can promote lymphatic targeting and prolong the 531 
retention of liposomes at lymph nodes after intramuscular injection, offer opportunities to deliver 532 
drugs or proteins to enhance lymphatic drug targeting. This targeting strategy does not translate to 533 
enhanced immune responses after vaccination with the DSPC:Chol:PS-biotin/avidin formulation.  534 
Conclusions 535 
Overall, our biodistribution studies confirm that the liposome formulations drained from the site of 536 
injection at different rates according to the composition, charge and size. However, upon clearing the 537 
injection site, the choice of lipid within the formulation also had an impact as liposomes containing PS 538 
showed higher accumulation at the draining lymph node compared to other anionic lipids. This may 539 
be due to preferential phagocytosis of the PS containing liposomes. Saturation of lymphatic uptake 540 
and lymph node localisation did not occur over a large liposomal lipid dose range (up to 480 µg/dose). 541 
These studies demonstrate that employing PS within small liposomes can promote lymphatic targeting 542 
after intramuscular injection. These liposomes were then surface modified with biotin so that avidin-543 
biotin complexes were formed at the draining lymphatics to promote retain of these liposomes. Using 544 
this avidin/biotin liposome system and employing microfluidics to manufacture liposomal 545 
formulations lead to production of smaller sized liposomes that can deliver loaded model protein to 546 
lymph node effectively.  547 
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List of Tables. 648 
Table 1: Physicochemical characteristics (particle size, PDI and ZP) and loading efficiency of the 649 
vaccine formulations prepared for the immunisation study. All vaccine formulations were loaded 650 
with a final H56 concentration of 0.1 mg/mL.  Non encapsulated antigen was removed by TFF in 651 
order to have the same antigen concentration in all the vaccines. 652 
Formulations Lipid ratio 
(µmoles) 
Particle size 
(nm) 
PDI Zeta Potential 
(mV) 
Antigen 
loading (%) 
DSPC:Cholesterol:PS 6:4:2.5 113.3 ± 2.3 0.15 ± 0.02 -41.1  ± 4.6 18.7 ± 4.3 
DSPC:Cholesterol:PS:DSPE-PEG 
2000 biotin (20 mole %) 
6:4:2.5 + 20 mole% 87.5 ± 6.7 0.24 ± 0.02 -11.5 ± 1.9 9.9 ± 3.2 
 653 
  654 
Figure Legends. 655 
Figure 1. The effect of charge on liposome biodistribution. Mice were injected intramuscularly with 4 656 
formulations, as shown in A. The rate of clearance from the injection site (B) and the popliteal lymph 657 
node (POP) (C) are shown as a percentage of injected dose. The degree of aggregation of these 658 
formulations when exposed to simulated interstitial fluid is shown in D. Results are expressed of the 659 
mean ± SD of 3 mice per group.  660 
Figure 2. The effect of formulation on liposome update by macrophages. The presence of 661 
phosphatidylserine in liposomes shown to increase association with THP-1 (macrophages) cells was 662 
investigated by flow cytometry. (A) Percentage of THP-1 cells positive for fluorescence surface 663 
bounded or internalized) with macrophages at 0 mins and 180 mins. (C) Fold increase of mean 664 
fluorescent intensity of THP-1 cells co-cultured with above liposome formulations. Results denote 665 
mean ± SD of 3 independent experiments.  666 
Figure 3 The effect of liposome size on the clearance of liposomes from the injection site to the local 667 
draining lymph node. DSPC:Chol:PS liposomes were formulated as MLV (A) and SUV (B). Mice were 668 
intramuscular (i.m.) injected with SUV and MLV liposomes and the liposomes at the injection site (C) 669 
and popliteal lymph node (PLN) (D) are shown. (E) Percentage of THP-1 cells positive for 670 
fluorescence surface bounded or internalized) with macrophages at 0 mins and 180 mins. (F) Fold 671 
increase of mean fluorescent intensity of THP-1 cells co-cultured with above liposome formulations. 672 
Results are expressed of the mean ± SD of 3 mice per group.  673 
Figure 4. The effect of lipid dose on lymphatic uptake in mice following intramuscular injection of 674 
liposome formulations. Increasing doses of DSPC:Chol:PS liposomes were injected and the amount 675 
of liposomes at the injection site measured and shown as (A) Amount of PS (µg) at Injection site, (B) 676 
Amount of PS (µg) at Popliteal lymph node (PLN), (C) Percent dose of DSPC:Cholesterol:PS liposomes 677 
at three different escalated doses at popliteal lymph nodes. Results are expressed of the mean ± SD 678 
of 3 mice per group 679 
Figure 5. The effect of exploiting a biotin-avidin complex system for lymphatic targeting. Mice were 680 
intramuscularly injected with either DSPC:Chol:PS:PEG2000 (6:4:2.5 µmoles; 2 mole% PEG) or 681 
DSPC:Chol:PS:PEG2000-biotin (6:4:2.5 µmoles; 2mole% PEG-biotin). Two groups of mice received the 682 
biotin-coated liposomes, one without pre-dosing of avidin (DSPC:Chol:PS:PEG2000-biotin) and one 683 
group receiving a pre-dose of avidin (DSPC:Chol:PS:PEG200-biotin-avidin). The percentage (%) 684 
injected dose of biotinylated liposomes in mice following intramuscular injection A: Injection site, B: 685 
Popliteal lymph node (POP), C: Inguinal lymph node (ILN) and D: Mesenteric lymph node (MLN). 686 
Results are expressed of the mean ± SD of 3 mice per group.  687 
Figure 6. Biodistribution of lymphatic targeted liposomes and antigen (H-56) in mice. Two liposome 688 
formulations were tested (avidin was intramusculary injected 2 hours prior injection of the main 689 
formulation). Liposomes and antigen dose was monitored at the site of injection (A & E), popliteal 690 
lymph node (B & F), Inguinal lymph node (C & G) and mesenteric lymph node (D & H) were isolated 691 
and counted for % injected dose of DSPC:Chol:PS and DSPC:Chol:PS:DSPE-PEG 2000 Biotin (20 692 
mole%) formulations respectively. Results represent the mean ± SD of three replicate batches (n = 693 
3). 694 
Figure S1. Antigen-specific (A) IgG1 and (B) IgG2c responses in mice immunised with liposomes with 695 
and without the biotin-avidin complex formulation. C57BL/6 mice were intramuscularly immunised 696 
with the liposomes incorporating H56 and humoural responses were analysed in blood. H56-specific 697 
IgG1 (A, B, C) and IgG2c (D, E, F) serum responses detected by ELISA on sera collected (A, D) 7, (B, E) 698 
21 and (C, F) 49 days after i.m. immunization. Antibody titres were expressed as the reciprocal log of 699 
the highest dilution with an OD value ≥0.2 after background subtraction. 700 
Figure S2. Cytokine production in splenocyte and lymph node culture supernatants (IL-17 and IFN-ɣ) 701 
in mice immunised with liposomes with and without the biotin-avidin complex system. C57BL/6 mice 702 
were intramuscularly immunised with H56 incorporated in the various liposome formulations and 703 
spleens were collected 3 weeks after the last immunization. Levels of IFN-ɣ in the spleen (A), 704 
popliteal lymph nodes (B), and IL-17 in the spleen (C) and lymph nodes (D) were measured. Values, 705 
expressed as picograms per milliliter, are reported as the mean value ± SD of H56-stimulated of five 706 
animals per group. 707 
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